David Dockhorn, CEO at Veranex, has 32 years of life sciences operating experience in various leadership roles. Early in his career, he was a co-founder of a full-service CRO that was sold to Carlyle in 1997 and integrated into PRA Health Sciences, Inc. (PRA). Most recently, he was executive vice president and chief compliance officer from January 2012 until March 2018. In this role, David led several divisions at PRA including global quality assurance, regulatory affairs, project management office, process and learning management, investigator contracts, talent acquisition, and vendor management.
Additionally, he was the global head of Phase I Operations and the Clinical Pharmacology Laboratories. These businesses represented roughly 2,500 FTEs and a budget of ~$750 million. David received his M.S. in physiological psychology from Pittsburgh State University and his Ph.D. in neuroscience from Texas Tech University.